Type 1 Diabetes
Improving Lives Today, Investing in a Better Tomorrow
Improving Lives Today, Investing in a Better Tomorrow
Helmsley’s Type 1 Diabetes (T1D) Program is dedicated to helping the global T1D community live safer, better, and more fulfilling lives today while funding advancements in research and technology for a better tomorrow. To make this vision a reality, our T1D program takes bold but informed risks to support researchers developing new therapies and interventions that can treat, prevent, or delay the disease. We are committed to equitable, affordable access to the tools that can help people with T1D achieve better outcomes. Every day counts for people with T1D and their support network, which is why we build collaborative partnerships to expand the availability of resources to these communities.
Over the last century, advances in therapies and technologies have drastically improved health and daily lives for many with T1D, but the risk of hospitalization and serious complications persists. Managing T1D remains a lifelong, often mentally-taxing challenge that complicates everyday decisions around diet, exercise, and health. It requires around-the-clock management of blood sugar and regular administration of insulin, a drug that can cause hypoglycemia — low blood sugar that can be fatal — if not dosed correctly. Meanwhile, treatments and technologies that can significantly reduce the burden of T1D are not available to everyone.
T1D is an autoimmune disease in which the immune system mistakenly attacks beta cells in the pancreas. Beta cells produce insulin, an essential hormone that allows the body to metabolize food. People with T1D depend on therapeutic insulin, administered multiple times a day, to regulate their blood sugar — without insulin, or if insulin is dosed improperly, T1D is fatal.
In addition to the destruction of insulin-producing beta cells, in T1D the neighboring alpha cells are also dysregulated. Alpha cells produce glucagon, a hormone important for the response to low blood sugar — which can also be life-threatening.
T1D can develop at any age. The exact causes of T1D are unknown, but genetics and environmental influences are believed to contribute.
Managing T1D can be incredibly taxing on people with T1D and their caregivers. Because the risk of death is real and immediate, at Helmsley, we’re committed to easing this burden and improving outcomes for all people living with T1D.
November 18, 2026
Many people living with diabetes generate health information through continuous glucose monitoring systems, automated insulin delivery systems, and other connected devices. But data alone does not improve outcomes — to fully realize the benefits from this data, it needs to be interpreted, actionable, and incorporated into existing healthcare workflows.
November 17, 2026
In 2025 alone, more than 600,000 people died from undiagnosed type 1 diabetes (T1D) — people who never had the chance to receive the treatment and care they needed. This World Diabetes Day, the theme of early action underscores the importance of early detection and uninterrupted access to lifelong care. This year, early action has a new engine worth celebrating:…
July 28, 2026
In late June, the World Health Organization Regional Office for Africa (WHO AFRO) hosted the third International Conference on PEN-Plus in Africa (ICPPA) in Dar es Salaam, Tanzania. This year, African health leaders didn’t come to hear about a promising pilot. They came to talk about scaling it. The discussion shifted from proving PEN-Plus works to building the systems needed to sustain it.
May 14, 2026
Washington, D.C. and New York, N.Y., May 14, 2026 — The National Committee for Quality Assurance (NCQA) is proud to announce new funding from The Leona M. and Harry B. Helmsley Charitable Trust to strengthen clinician and health plan accountability for delivering high‑quality diabetes care. The three‑year initiative will advance quality of care for people living with type 1 and…
April 8, 2026
Helmsley Type 1 Diabetes Program Officer James Reid joined Jayasree Iyer on the Access to Medicine Foundation’s Health Equity Podcast to talk about closing the gap in type 1 diabetes care for people in low- and middle-income countries. As James puts it, “What really matters is how we align our resources, our will, and our efforts to make sure…
February 5, 2026
Hypoglycemia, or low blood sugar, is a dangerous complication of type 1 diabetes. It can lead to shakiness or confusion and in extreme cases, seizures, loss of consciousness, or even death. Frustratingly, too much insulin — the drug that people with type 1 diabetes (T1D) rely on daily to manage their blood sugar — can cause hypoglycemia. Diet and exercise…
$1.1B
committed
840+
grants awarded
50+
countries reached